Summary of the Conference Call on the Pharmaceutical Industry Industry Overview - The pharmaceutical industry is currently experiencing a period of adjustment, particularly in the innovative drug sector, with leading companies like Innovent Biologics and China National Pharmaceutical Group showing stable fundamentals and product progress meeting expectations [1][4] - The overall sentiment in the pharmaceutical sector remains optimistic despite recent market fluctuations, with no signs of a bubble [2] Key Points and Arguments Innovative Drug Sector - The innovative drug sector is undergoing a rational adjustment, with a focus on companies that can deliver strong performance [3] - The 11th round of national drug procurement is expected to yield positive results, with local alliance procurement rules becoming more reasonable, potentially leading to a reversal in the generics sector [3][20] - Companies such as Kanglong Chemical, Baidu Pharmaceutical, Tianyu Co., and Betta Pharmaceuticals are projected to see significant revenue growth [3][24] Medical Device Sector - The medical device sector is benefiting from a reduction in competitive pressures, particularly in high-value consumables like Nanwei Medical and Xinmai Medical, which have not yet faced centralized procurement [5] - The orthopedic industry is recovering from previous procurement pressures, with companies like Chunli Aikang showing strong performance [5] - Companies focused on domestic bidding markets, such as Mindray and Kaili Medical, are expected to benefit from this trend [5] Customized Consumables - The customized consumables sector is performing well, with Yingke Medical exceeding profit expectations in Q2 and extending order schedules into Q3, indicating a recovery in end-user demand [6] IVD Sector - The IVD sector is under pressure due to policy changes and tax rate adjustments, but the bottom has been solidified, with companies like Mindray and New Industries showing strong overseas export performance [7] Traditional Chinese Medicine - Recommended companies in the traditional Chinese medicine sector include Jiuzhitang, Kangyuan Pharmaceutical, and China Resources Sanjiu, with Jiuzhitang showing significant potential in its stem cell pipeline [8] API Sector - The API sector is expected to benefit from anti-involution policies, leading to a new round of supply-side reforms [1][15] - Companies like Tianyu Co. are experiencing rapid capacity utilization increases, with projected profits exceeding 300 million yuan [15][18] Additional Insights - The blood products sector is facing pressure but is nearing a stabilization point, with new developments in high-purity products expected to create investment opportunities [22] - The raw material industry is anticipated to see long-term improvements due to government policies aimed at reducing chaotic price competition [15][18] - New delivery systems and commercialization scenarios in the pharmaceutical industry, such as Minophagen's GLP-1 delivery system, are gaining attention and providing more investment opportunities [17] Conclusion - The pharmaceutical industry, particularly the innovative drug and medical device sectors, presents a range of investment opportunities despite current market challenges. Companies with strong fundamentals and innovative pipelines are likely to perform well in the coming quarters [1][2][3][4][5][6][7][8][15][18][22]

Core Insights - The domestic BD (business development) transactions in the pharmaceutical industry have exceeded the total amount for the entire year of 2024, indicating an improvement in the quality of China's pharmaceutical sector [1][2] - The second-tier market is showing signs of recovery, driven by improved performance of listed pharmaceutical companies and the introduction of significant policies [3][4] - Despite the positive trends in the second-tier market, the first-tier market remains sluggish, with a notable decline in private financing events and total transaction amounts [4][5] Group 1: BD Transactions and Market Performance - In the first half of the year, domestic BD transactions totaled 72, with upfront payments reaching $2.6 billion and total transaction amounts hitting $60 billion, surpassing the total for 2024 [2] - Leading pharmaceutical companies like Heng Rui and BeiGene reported significant revenue growth, with Heng Rui achieving a revenue of 15.76 billion yuan, a year-on-year increase of 15.88%, and BeiGene reporting 17.52 billion yuan, up 46.03% [2] - Among 499 pharmaceutical and biotechnology companies, 236 reported a year-on-year increase in net profit, accounting for 47.3% of the total, reflecting a slight improvement from the previous year [2] Group 2: Policy Impact and Market Sentiment - The introduction of policies such as "Measures to Support the High-Quality Development of Innovative Drugs" has bolstered market confidence, contributing to a 17% increase in the biopharmaceutical index since the beginning of 2025 [3][4] - The industry has experienced a shift in perception regarding BD transactions, with many now viewing them as a vital pathway for internationalization rather than a concern of "selling seedlings" [3][4] Group 3: Challenges in the First-tier Market - The first-tier market is experiencing a "wait for the wind" situation, with over 300 private financing events reported in the first half of 2025, but transaction numbers and total amounts have been declining [4][5] - The low pricing of innovative drugs in China compared to global markets has led to a "high risk, low return" scenario, deterring new entrants and limiting the growth of new biopharmaceutical funds [4][5] - External uncertainties, such as the recent U.S. government proposal to impose high tariffs on various imported products, including patented drugs, have created additional challenges for the industry [4][5] Group 4: Industry Outlook and Market Expansion - Industry insiders emphasize the need for domestic market expansion, particularly through the development of commercial insurance and optimization of innovative drug pricing mechanisms [1][6][8] - The potential for growth in the domestic pharmaceutical market remains significant, with healthcare spending in China currently at 7.9% of GDP compared to 17.7% in the U.S., indicating room for expansion [7][8] - As living standards rise, there is an increasing focus on health, which could provide long-term support for the pharmaceutical industry [8]

Market Review - The CITIC Pharmaceutical Index decreased by 1.98%, underperforming the CSI 300 Index by 1.54 percentage points, ranking 22nd among 30 CITIC first-level industries [7] - The top ten stocks by increase this week included Xiangrikui, Aopu Mai, and Xinlitai, with increases of 57.86%, 23.89%, and 15.81% respectively [7][37] - The top ten stocks by decrease included Borui Pharmaceutical and Jimin Health, with decreases of 38.36% and 19.65% respectively [7][37] Overall View and Investment Themes - The pharmaceutical sector is currently undervalued, with public funds (excluding pharmaceutical funds) having low allocation to the sector. The company maintains an optimistic outlook for the growth of the pharmaceutical industry in 2025, expecting diverse investment opportunities [12] - The innovative drug sector is transitioning from quantity to quality, focusing on differentiated and internationalized pipelines. Companies that can deliver profitable products are expected to be favored [12] - In the medical device sector, there is a noticeable recovery in bidding volumes for imaging equipment, and home medical devices are benefiting from subsidy policies. The company suggests focusing on key players in these areas [12] - The life sciences service sector is expected to see a rebound in overseas investment and domestic demand, with a focus on CXO and life science services as a growth driver [12] - The pharmaceutical industry is anticipated to enter a new growth cycle, particularly in the specialty raw materials sector, which is expected to benefit from cost improvements and low valuations [12] Industry and Individual Stock Events - The Chinese traditional medicine sector is expected to see growth driven by basic drug reforms and national enterprise reforms, with a focus on companies like Kunming Pharmaceutical Group and Kangyuan Pharmaceutical [10][31] - The medical service sector is expected to improve due to anti-corruption measures and centralized procurement, enhancing the competitiveness of private medical institutions [13][26] - The blood products sector is projected to grow significantly during the 14th Five-Year Plan period, with increased approval for plasma stations and expanding product offerings [13] - The medical device market is experiencing a shift towards domestic alternatives, particularly in high-value consumables and imaging equipment, with significant growth expected in 2024 and beyond [20][21] 2025Q3 Pharmaceutical Performance Outlook - Expected revenue growth rates for various companies in Q3 2025 range from 0% to over 60%, with notable mentions including Bai Pu Sai Si and Kanglong Huacheng [14] - The innovative drug sector is expected to see significant contributions from companies like Betta Pharmaceuticals and Hengrui Medicine, with growth rates projected between 10% and 30% [14] Investment Recommendations - The company recommends focusing on the pharmaceutical retail sector, particularly in light of the accelerating trend of prescription outflow and the optimization of competitive dynamics [25] - In the medical device sector, attention is drawn to companies benefiting from the recovery in bidding for imaging equipment and the growth of home medical devices [20] - The life sciences service sector is highlighted for its potential recovery and growth opportunities, particularly in overseas markets [24]

恒生指数冲高回落，截止目前恒生指数下跌1.08%。其中恒生科技跌幅居前，恒生工商、国指ESG等紧 随其后；内房地、内石油。公用等逆势小涨。 恒生工商低开低走，截至目前下跌1.33%，其中携程集团下跌2.01%，中国生物制药、紫金矿业、信义 光能、安踏体育、网易、周大福等今20只个股跌幅在1%上方。 内房地探底回升，盘中一度下跌1.36%，截至目前微跌0.02%。其中万物云下跌0.92%，九龙仓集团、建 发国际、贝壳、华润万象生活等股均小幅下跌；越秀地产、海外发展、华润置地等股均小幅上涨。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 恒生科技大幅低开后冲高回落，截止目前下跌1.21%，其中地平线机器人大跌5.75%，小米集团下跌 4.79%，金山软件下跌4.26%，金蝶国际下跌3.68%，京东健康、阿里健康、京东集团等超10只个股跌幅 均在2%上方。 ...

Core Viewpoint - The 2025 Capital International Medical Conference's parallel forum, the China-UK Medical Technology Innovation Summit, emphasizes collaboration and development in the medical technology sector between China and the UK, aiming to enhance global public health initiatives [1][3]. Group 1: Collaboration and Innovation - Medical technology innovation is a key pillar of national innovation systems and is essential for advancing the Healthy China strategy and improving public health [3]. - The China Hospital Association and BMJ Group are fostering a collaborative environment to enhance medical technology cooperation between China and the UK, focusing on practical and extensive partnerships [3][6]. - Specific initiatives proposed include addressing major health issues, promoting interdisciplinary collaboration, and enhancing talent development through joint participation of universities, hospitals, and enterprises [4][10]. Group 2: Ecosystem and Policy Support - The UK has developed a comprehensive innovation ecosystem supported by policies that facilitate research, technology transfer, and industrial application, while China is transitioning from a "big pharmaceutical country" to a "strong pharmaceutical country" [8][9]. - Beijing is positioning itself as a core area for high-quality development in the pharmaceutical and health industry, implementing various innovative policies and programs to enhance clinical research and drug development [9][10]. Group 3: Internationalization and Market Potential - The global innovation drug market has seen significant growth, with China emerging as a key player in clinical research and drug development, evidenced by a substantial increase in licensing fees and clinical trial projects [11]. - The Chinese medical device market is projected to reach 1.3 trillion yuan in 2023, indicating a 17% year-on-year growth, although there remains a gap in the drug-to-device ratio compared to global averages [12]. Group 4: AI and Future Directions - AI technology is increasingly being integrated into medical innovation, although challenges such as data compatibility and clinical demand alignment persist [14]. - The potential for AI to enhance clinical data management and improve healthcare delivery is recognized, with recommendations for developing interdisciplinary talent in AI and healthcare [14][15]. Group 5: Sustainable Cooperation Mechanisms - Establishing sustainable cooperation mechanisms is crucial for maximizing the value of medical technology innovation globally, with emphasis on strategic alignment, research matching, and talent training [15][16]. - The UK and China are encouraged to deepen data sharing and collaborative research to address common health challenges, leveraging each country's strengths in data resources and clinical applications [17][18].

(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） （Stock Code 股份代號：1177） NOTIFICATION LETTER 通知信函 Dear Non-Registered Shareholders, Sino Biopharmaceutical Limited (the "Company") – Notice of publication of 2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are now available on the Company's website at www.sinobiopharm.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock ...

(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） （Stock Code 股份代號：1177） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders, 26 September 2025 Sino Biopharmaceutical Limited (the "Company") – Notice of publication of 2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are now available on the Company's website at www.sinobiopharm.com and the website of The Stock Exchange of Hong Kong Limit ...

SINO BIOPHARMACEUTICAL LIMITED ( 於開曼群島註冊成立之有限公司) (股票編號：1177) 中期報告 2025 Interim Report 2025 中期報告 公司資料 公司法定名稱 中國生物製藥有限公司 股票代號 1177 公司網址 www.sinobiopharm.com 公司註冊地點 開曼群島 主板上市日期 二零零三年十二月八日 創業板上市日期 二零零零年九月二十九日 董事 執行董事 謝其潤女士 （主席） 謝炳先生 （資深副主席） 鄭翔玲女士 （副主席） 謝承潤先生 （首席執行長） 謝炘先生 田舟山先生 獨立非執行董事 陸正飛先生 李大魁先生 魯紅女士 張魯夫先生 李國棟醫生 執行董事委員會 謝其潤女士 （主席） 謝炳先生 鄭翔玲女士 謝承潤先生 謝炘先生 審核委員會 陸正飛先生 （主席） 李大魁先生 魯紅女士 李國棟醫生 薪酬委員會 張魯夫先生 （主席） 陸正飛先生 魯紅女士 提名委員會 謝其潤女士 （主席） 謝炳先生 陸正飛先生 魯紅女士 張魯夫先生 李國棟醫生 環境、社會及管治委員會 鄭翔玲女士 （主席） 謝其潤女士 李國棟醫生 公司秘書 陳凱年先生 授權代表 謝炳 ...

Core Viewpoint - The article discusses the impact of U.S. President Trump's announcement to impose a 100% tariff on patented and branded drugs starting October 1, which has led to significant declines in pharmaceutical stocks across major Asian markets [1][3]. Market Reactions - Major pharmaceutical stocks in Asia experienced declines, with Japan's Topix Pharma Index falling by 1.39%. Notable declines included Daiichi Sankyo at 3.34%, Chugai Pharmaceutical at 2.18%, and Sumitomo Pharma at 3.03% [3]. - In South Korea, significant pharmaceutical stocks like Samsung Biologics and SK Biopharmaceuticals dropped by 1.66% and 2.66%, respectively, contributing to a 2.56% decline in the KOSPI index [3][6]. - In Hong Kong, the HSBIO index opened down approximately 2.58%, with Wuxi Biologics leading the decline at 2.95% before narrowing to 2.10% [6]. Economic Implications - Economists from the Commonwealth Bank of Australia noted that the market had already anticipated further tariffs and industry investigations, predicting an increase in the effective tariff rate from about 10% in August to around 18% in the coming months [8][9]. - The focus is shifting towards the impact of these tariffs on the Indian stock market, which opened with a 0.38% decline. The U.S. accounts for over one-third of India's pharmaceutical exports, primarily consisting of low-cost generic drugs [9][10]. Investment Trends - The Indian stock market has faced ongoing pressure due to U.S. tariff policies, with significant foreign portfolio investors selling over $17 billion worth of Indian stocks by 2025. Recent sales amounted to ₹499.5 billion (approximately $5.63 million) [10]. - The Nifty 50 and Sensex indices have both dropped over 2% in the past five trading days, marking the longest decline in six months [10].

Core Viewpoint - The announcement of a 100% tariff on patented and branded drugs by the U.S. government is expected to impact pharmaceutical stocks in the short to medium term [1][9]. Group 1: Market Reactions - Major pharmaceutical stocks in Asia experienced declines following the tariff announcement, with the Topix Pharma Index in Japan dropping by 1.39% [3]. - Specific companies such as Daiichi Sankyo, Chugai Pharmaceutical, and Sumitomo Pharma saw declines of 3.34%, 2.18%, and 3.03% respectively [3]. - In South Korea, Samsung Biologics and SK Bio Pharmaceuticals fell by 1.66% and 2.66%, contributing to a 2.56% drop in the KOSPI index [3]. - Hong Kong's pharmaceutical sector was among the largest decliners, with the HSBIO index opening down approximately 2.58% [5]. Group 2: Economic Implications - Economists predict that the effective tariff rate will rise from about 10% in August to around 18% in the coming months, although the broader impact on economies like Japan and Australia is expected to be limited [7]. - The Indian stock market is particularly sensitive to these tariffs, as the U.S. accounts for over one-third of India's pharmaceutical exports, primarily generic drugs [7]. - The Nifty 50 index in India saw a decline of 0.38% shortly after the market opened, reflecting the negative sentiment [7]. Group 3: Investment Trends - The new tariffs are anticipated to exert pressure on the Indian stock market, which has already faced challenges this year due to U.S. tariff policies and new visa regulations [9]. - Foreign portfolio investors have sold over $17 billion worth of Indian stocks, with a recent sell-off of approximately $563 million [9]. - The Nifty 50 and Sensex indices have both dropped over 2% in the past five trading days, marking the longest decline in six months [9].